Patients at high risk for fracture may need a different approach. FORTEO is the only FDA-approved anabolic agent for the treatment of osteoporosis. This section is designed to illustrate the anabolic action of FORTEO in the treatment of osteoporosis for patients at high risk for fracture.
MicroCT images are of paired iliac crest bone biopsies at baseline and after 21 months of treatment with FORTEO. These biopsies are from a postmenopausal patient with a baseline T-score of –2.7 at the total hip who had a BMD response that was representative of the treatment group.1 *In a trial of 1,637 postmenopausal women given the study drug or placebo for a median duration of 19 months (maximum 24 months).
1Data on file, Lilly Research Laboratories (FOR20070809A). Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant Human Parathyroid Hormone (1-34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure. J Bone Miner Res 2003;18:1932–1941
Last Update: 27 Oct 15